MYDA Advisors’s Mereo BioPharma MREO Stock Holding History

MYDA Advisors’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-21,502	Closed	-$19K	–	111
2022 Q3	$19K	Sell	21,502 -8,498	-28%	-$10.4K	0.01%	150
2022 Q2	$34K	Buy	+30,000	New	+$23.2K	0.01%	178

Other funds holding MREO

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

MYDA Advisors's MREO Position: Q4 2022 in Review

MYDA Advisors sold out of Mereo BioPharma (MREO) in Q4 2022, closing a stake of 21,502 shares — an estimated $19K sold.

MYDA Advisors first reported a position in MREO in Q2 2022 and held it in 2 quarters. The position peaked at $34K in Q2 2022. 61 funds tracked by Wall St. Rank hold MREO as of Q4 2022.

MYDA Advisors reported no remaining Mereo BioPharma position as of Q4 2022 after selling out during the quarter.
MYDA Advisors sold 21,502 Mereo BioPharma shares in Q4 2022, an estimated $19K.
MYDA Advisors first reported a position in Mereo BioPharma in Q2 2022 and held it in 2 quarters.
MYDA Advisors's Mereo BioPharma position peaked at $34K in Q2 2022.
61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2022.

Based on MYDA Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.